| Effect of long- and short-term treatments with pravastatin on diabetes mellitus and pancreatic fibrosis in the Otsuka-Long-Evans-Tokushima fatty rat. | |
| | |
MedLine Citation:
|
PMID: 20015084 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND PURPOSE: The effects of statins on diabetes mellitus (DM) are controversial, and their effects on pancreatic fibrosis are poorly defined. We investigated the effect of long- and short-term treatments with pravastatin on the development of DM and pancreatic fibrosis in DM-prone Otsuka-Long-Evans-Tokushima Fatty (OLETF) rats. EXPERIMENTAL APPROACH: Male OLETF rats were divided into four groups at 12 weeks of age. The first group received a standard rat diet until the end of the experimental period at age 80 weeks. The second group was given a diet containing 0.05% pravastatin from 12 weeks of age, before the onset of DM and pancreatic fibrosis, and the third group was given the same pravastatin diet from 28 weeks of age, after the onset of DM and pancreatic fibrosis, until age 80 weeks. The fourth group received the same pravastatin diet only for 16 weeks, from 12 to 28 weeks of age, and switched to a standard diet. Progressions of DM and pancreatic fibrosis were evaluated. KEY RESULTS: Long-term treatments with pravastatin, either from 12 or 28 weeks of age, decreased serum glucose concentration and fibrotic area, elevated superoxide dismutase activity and down-regulated transforming growth factor-beta1 mRNA in the pancreas. In contrast, after a short-term treatment with pravastatin, these parameters markedly deteriorated after its cessation. CONCLUSIONS AND IMPLICATIONS: The results suggest that long-term treatment with pravastatin improves DM and pancreatic fibrosis via anti-oxidative and anti-fibrotic properties, whereas cessation of pravastatin abolishes these beneficial effects, and accelerates DM and pancreatic fibrosis. |
| | |
Authors:
|
M Otani; M Yamamoto; M Harada; M Otsuki |
Related Documents
:
|
22078494 - Probucol alleviates atherosclerosis and improves high density lipoprotein function. 7039364 - Dietary modulation of alpha-cell volume and function in strain 129/j mice. 3435264 - Pancreatic steatorrhea: action of a total lyophilized pancreas preparation: an "in vitr... 6186444 - Effect of chronic ethanol feeding on pancreatic enzyme secretion in rats in vitro. 6805304 - Enteral nutrition by nasogastric tube in adult patients treated with intensive chemothe... 19386004 - Effect of dietary alpha-tocopherol + ascorbic acid, selenium, and iron on oxidative str... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-12-15 |
Journal Detail:
|
Title: British journal of pharmacology Volume: 159 ISSN: 1476-5381 ISO Abbreviation: Br. J. Pharmacol. Publication Date: 2010 Jan |
Date Detail:
|
Created Date: 2010-02-09 Completed Date: 2010-05-10 Revised Date: 2011-07-19 |
Medline Journal Info:
|
Nlm Unique ID: 7502536 Medline TA: Br J Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 462-73 Citation Subset: IM |
Affiliation:
|
Department of Gastroenterology and Metabolism, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adipose Tissue, White
/
drug effects,
pathology Animals Apoptosis / drug effects Blood Glucose / analysis Cholesterol / blood Diabetes Mellitus, Type 1 / drug therapy*, metabolism, pathology Fatty Acids, Nonesterified / blood Fibrosis Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* Insulin / blood Insulin Resistance Male Organ Size / drug effects Pancreas / drug effects*, metabolism, pathology Peroxidase / metabolism Pravastatin / therapeutic use* Rats Rats, Long-Evans Superoxide Dismutase / metabolism Time Factors Transforming Growth Factor beta1 / biosynthesis Triglycerides / blood Tumor Necrosis Factor-alpha / biosynthesis |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Fatty Acids, Nonesterified; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Transforming Growth Factor beta1; 0/Triglycerides; 0/Tumor Necrosis Factor-alpha; 11061-68-0/Insulin; 57-88-5/Cholesterol; 81093-37-0/Pravastatin; EC 1.11.1.7/Peroxidase; EC 1.15.1.1/Superoxide Dismutase |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials.
Next Document: Effects of chronic sympatho-inhibition on reflex control of renal blood flow and plasma renin activi...